(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.30%) $79.19
(0.10%) $2.04
(0.13%) $2 312.60
(0.25%) $26.90
(0.02%) $962.80
(-0.05%) $0.932
(-0.06%) $10.98
(-0.05%) $0.797
(-0.02%) $91.11
Live Chart Being Loaded With Signals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States...
Stats | |
---|---|
Šios dienos apimtis | 142 640 |
Vidutinė apimtis | 235 521 |
Rinkos kapitalizacija | 81.26M |
EPS | €0 ( 2024-03-27 ) |
Kita pelno data | ( €-0.240 ) 2024-05-08 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.640 |
ATR14 | €0.00900 (0.65%) |
Tūris Koreliacija
Inflarx NV Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
NVTS | -0.839 |
SFIX | -0.811 |
TRNS | -0.809 |
MBINO | -0.808 |
SKYW | -0.804 |
RVNC | -0.802 |
WPRT | -0.802 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Inflarx NV Koreliacija - Valiuta/Žaliavos
Inflarx NV Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €61 795.00 |
Bruto pelnas: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2023 |
Pajamos: | €61 795.00 |
Bruto pelnas: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2022 |
Pajamos: | €0 |
Bruto pelnas: | €-585 852 (0.00 %) |
EPS: | €-0.610 |
FY | 2021 |
Pajamos: | €0.00 |
Bruto pelnas: | €0.00 (0.00 %) |
EPS: | €-1.100 |
Financial Reports:
No articles found.
Inflarx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.